Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).
Ascletis Pharma Inc. has announced its intention to repurchase up to 96,284,628 shares, equivalent to 10% of its issued shares, under a repurchase mandate approved by shareholders. The company plans to use up to HK$300 million of its internal financial resources for this initiative, aiming to enhance shareholder value and reflect confidence in its long-term business prospects. The repurchase will be conducted in compliance with relevant regulations and will not adversely impact the company’s financial position.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$10.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a pharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative drugs. The company is listed on the Hong Kong Stock Exchange and is involved in the biopharmaceutical industry.
Average Trading Volume: 9,020,184
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.67B
Find detailed analytics on 1672 stock on TipRanks’ Stock Analysis page.